| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Opus Genetics, Inc. | Chief Financial Officer | Common Stock | 194K | $223K | $1.15 | 13 Mar 2025 | Direct |
| Opus Genetics, Inc. | Chief Financial Officer | Employee Stock Option (right to buy) | 52.5K | 13 Mar 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | 13 Mar 2025 | 2 | $0 | 4 | Chief Financial Officer | 17 Mar 2025, 20:52 |
| IRD | Opus Genetics, Inc. | 13 Feb 2025 | 1 | -$9.44K | 4 | Chief Financial Officer | 18 Feb 2025, 16:05 |
| OCUP | Ocuphire Pharma, Inc. | 21 Mar 2024 | 1 | $21K | 4 | Chief Financial Officer | 25 Mar 2024, 16:40 |
| OCUP | Ocuphire Pharma, Inc. | 12 Feb 2024 | 2 | $0 | 4 | Chief Financial Officer | 14 Feb 2024, 18:37 |
| OCUP | Ocuphire Pharma, Inc. | 12 Feb 2024 | 0 | $0 | 3 | Chief Financial Officer | 14 Feb 2024, 18:32 |